 NASHUA, N.H., Aug. 10, 2020 GLOBE NEWSWIRE -- iCAD, Inc. NASDAQ: ICAD, a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that Michael Klein, Chairman and Chief Executive Officer, will present a corporate overview at the Guggenheim MedTech Disruptors Summit, taking place virtually on August 10-11, 2020. Presentation DetailsDate: August 11, 2020Time: 3:00pm Eastern TimeAbout iCAD, Inc.Headquartered in Nashua, NH, iCAD is a global medical technology leader providing innovative cancer detection and therapy solutions.ProFound AITM is a high-performing workflow solution for 2D and 3D mammography, or digital breast tomosynthesis DBT, featuring the latest in deep-learning artificial intelligence. In 2018, ProFound AI for Digital Breast Tomosynthesis DBT became the first artificial intelligence AI software for DBT to be FDA-cleared; it was also CE marked and Health Canada licensed that same year. It offers clinically proven time-savings benefits to radiologists, including a reduction of reading time by 52.7 percent, thereby halving the amount of time it takes radiologists to read 3D mammography datasets. Additionally, ProFound AI for DBT improved radiologist sensitivity by 8 percent and reduced unnecessary patient recall rates by 7.2 percent.iThe Xoft System is FDA-cleared, CE marked and licensed in a growing number of countries for the treatment of cancer anywhere in the body. It uses a proprietary miniaturized x-ray source to deliver a precise, concentrated dose of radiation directly to the tumor site, while minimizing risk of damage to healthy tissue in nearby areas of the body.For more information, visit and Contacts: Media inquiries: Jessica Burns, iCAD 1-201-423-4492 Relations: Jeremy Feffer, LifeSci Advisors 1-212-915-2568 Conant, E. et al. 2019. Improving Accuracy and Efficiency with Concurrent Use of Artificial Intelligence for Digital Breast Tomosynthesis. Radiology: Artificial Intelligence. 1 4. Accessed via 